SynBiotic SE takes over GECA Pharma:

Entry into the medical cannabis market

Munich, May 19, 2021 - The cannabis company SynBiotic SE takes over 100 percent of Cologne-based GECA Pharma GmbH.

The cannabis company SynBiotic SE takes over 100 percent of Cologne-based GECA Pharma GmbH. With its expert knowledge and the necessary licenses, GECA Pharma will in future form the pharmaceutical arm of SynBiotic SE. Lars Müller, CEO of SynBiotic SE, says of the strategic importance of the acquisition: "The takeover of GECA Pharma is an important step for us. As one of the first German cannabis companies listed on the stock exchange, we are opening up the market for medicinal cannabis." According to Müller, the market in the EU will be worth several billion euros in the future. SynBiotic SE can participate through GECA Pharma and bring its own cannabis brands onto the market.

Also for Johannes Gallois, Managing Director of GECA Pharma, the inclusion of his company in the company portfolio of the platform company SynBiotic SE is the right course: "With SynBiotic SE we have found a partner who thinks 'Beyond Cannabis', i.e. beyond CBD or THC - medical Cannabis is just the beginning. Coupled with our many years of experience in the German cannabis market, this partnership is an absolute win for both sides. " SynBiotic SE CEO Müller understands "Beyond Cannabis" to mean "extracting cannabinoid and terpene-containing extracts from other plants such as hops or cocoa in order to produce new food supplements and herbal medicinal products on this basis". In the future, these products should help people with their sleep disorders, pain or anxiety - the three biggest social problems of our time.

In line with Lars Müller's acquisition strategy, GECA Pharma is already profitable and has a turnover of almost 900,000 euros from the trade in medicinal cannabis flowers alone. The company has all the necessary licenses: the wholesale license in accordance with Section 52a of the German Medicines Act, the license to handle narcotics and the license to place drugs on the market in accordance with the AMRad regulation. In the past few months, SynBiotic SE had already made two further investments: the hemp startup The Hempany with the hemp milk hemi and the Canadian R&D platform for cannabinoids NeuroTheryX.

Firmenlogo.png

Press Release

About SynBiotic SE

SynBiotic SE is the first German listed cannabis company and pursues a buy & build investment approach that is focused on the EU. The core business of the platform company is the research and development of new cannabinoid and terpene-based solutions for major social problems such as pain, sleep and anxiety. In addition, the platform deals with the production of various cannabinoids and develops and sells medicinal and nutritional supplements as well as cosmetic products under its own brands.​

 

 

About GECA Pharma GmbH

GECA Pharma GmbH, founded in 2017, is a Cologne-based pharmaceutical wholesale company that stands for quality, reliability and competence. The independent and GDP-certified (Good Distribution Practice) company has specialized in the import and nationwide distribution of high-quality cannabis products.

As a reliable link between manufacturers and pharmacies, GECA Pharma GmbH is in possession of a wholesale license in accordance with Section 52a of the German Medicines Act, a license to handle narcotic drugs and a license to market drugs in accordance with the AMRad regulation.

 

GECA Pharma GmbH

Public Relations

Eupener Straße 124

50933 Cologne Germany


Phone    + 49 221 4230 63 49

E-Mail      presse@geca-pharma.de

Internet   www.geca-pharma.de